FDA clears Xalkori for inflammatory myofibroblastic tumours

Pfizer's tyrosine kinase inhibitor Xalkori has picked up a fourth approval from the FDA, adding a new use in the treatment of a rare form of benign tumour that typically affects children an

Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early...

Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial.

Takeda sets sights on first-line lung cancer market with new...

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).

Xalkori gains NICE approval after price cut

NICE approval secured against background of renewed controversy